Switching the Chemoselectivity in the Preparation of [18F]FNA-N-CooP, a Free Thiol-Containing Peptide for Targeted Positron Emission Tomography Imaging of Fatty Acid Binding Protein 3

Pyry Dillemuth, Petter Lövdahl, Tuomas Karskela, Abiodun Ayo, Jesse Ponkamo, Heidi Liljenbäck, Sami Paunonen, Jonne Kunnas, Johan Rajander, Olli Tynninen, Jessica M. Rosenholm, Anne Roivainen, Pirjo Laakkonen, Anu J. Airaksinen, Xiang-Guo Li

Research output: Contribution to journalArticleScientificpeer-review

3 Citations (Scopus)
4 Downloads (Pure)

Abstract

Fatty acid binding protein 3 (FABP3) is expressed both in tumor cells and in the tumor vasculature, making it a potential target for medical imaging and therapy. In this study, we aimed to radiolabel a CooP peptide with a free amino and thiol group, and evaluate the radiolabeled product [18F]FNA-N-CooP for imaging FABP3 expression in breast cancer brain metastases by positron emission tomography. [18F]FNA-N-CooP was prepared by highly chemoselective N-acylation and characterized using different chemical approaches. We validated its binding to the target using in vitro tissue section autoradiography and performed stability tests in vitro and in vivo. [18F]FNA-N-CooP was successfully synthesized in 16.8% decay-corrected radiochemical yield with high radiochemical purity (98.5%). It exhibited heterogeneous binding on brain metastasis tissue sections from a patient with breast cancer, with foci of radioactivity binding corresponding to FABP3 positivity. Furthermore, the tracer binding was reduced by 55% in the presence of nonradioactive FNA-N-CooP a blocker, indicating specific tracer binding and that FABP3 is a viable target for [18F]FNA-N-CooP. Favorably, the tracer did not bind to necrotic tumor tissue. However, [18F]FNA-N-CooP displayed limited stability both in vitro in mouse plasma or human serum and in vivo in mouse, therefore further studies are needed to improve the stability [18F]FNA-N-CooP to be used for in vivo applications.
Original languageEnglish
Pages (from-to)4147-4156
JournalMolecular Pharmaceutics
Volume21
Issue number8
DOIs
Publication statusPublished - 5 Aug 2024
MoE publication typeA1 Journal article-refereed

Funding

This research was partially supported by the Research Council of Finland\u2019s Flagship InFLAMES and the funding decision numbers were 337 530 and 357 910. We thank the research grants from the Finnish Cancer Foundation, Sigrid Juse\u0301lius Foundation, the Finnish Cultural Foundation, Research Council of Finland (#350117), the Turku University Foundation, and State Research Funding of Turku University Hospital (#11009). The Turku Proteomics Facility, supported by Biocenter Finland, conducted mass spectrometry analyses for our study. The Histocore unit at the University of Turku performed the H&E staining. Digitization of tissue staining was performed using a 3DHISTECH Pannoramic 250 FLASH II slide scanner at the Genome Biology Unit, which is supported by HiLIFE, the Faculty of Medicine at the University of Helsinki, and Biocenter Finland.

Fingerprint

Dive into the research topics of 'Switching the Chemoselectivity in the Preparation of [18F]FNA-N-CooP, a Free Thiol-Containing Peptide for Targeted Positron Emission Tomography Imaging of Fatty Acid Binding Protein 3'. Together they form a unique fingerprint.

Cite this